Novartis Vaccines and Diagnostics, Inc., Cambridge, Mass., is being awarded a $14,189,402 technology investment agreement. The goal of this agreement is for Novartis to perform a research and development program designed to develop a self-replicating RNA vaccine platform.
Work will be performed in Cambridge, Mass. Work is expected to be completed by November 2015. The Defense Advanced Research Projects Agency is the contracting activity (HR0011-12-3-0001).